FOLH1 and prostate carcinoma: The nuclear medicine team in Heidelberg reported in 2014 that PET/CT with PSMA-11 (also known as PSMA-HBED-CC), a 68Ga-labelled ligand of the prostate-specific membrane antigen (PSMA), can evidence prostate cancer (PC) tissue undetected with 18F-fluorocholine (FCH) [1].